Cosela

Malignant Neoplasms, Therapeutic procedure, Pharmacotherapy + 2 more
Treatment
13 Active Studies for Cosela

What is Cosela

TrilaciclibThe Generic name of this drug
Treatment SummaryTrilaciclib (G1T28) is a medication used to reduce the risk of chemotherapy-induced myelosuppression (lowered blood cell counts) in patients undergoing certain types of chemotherapy for extensive stage small cell lung cancer. This medication works by inhibiting two specific proteins, CDK4 and CDK6, which are known to be involved in tumor growth and the effectiveness of chemotherapy. Trilaciclib was first introduced in 2016 and was approved by the FDA in 2021.
Coselais the brand name
Cosela Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Cosela
Trilaciclib
2021
1

Effectiveness

How Cosela Affects PatientsTrilaciclib is used to reduce the risk of low blood cell counts caused by certain types of chemotherapy. It is effective for about 16 hours, and must be taken carefully because it has a very narrow therapeutic window. Patients should be aware that taking this drug can cause injection site reactions, hypersensitivity, and lung disease.
How Cosela works in the bodyTrilaciclib is a drug that can help protect healthy cells from chemotherapy. It works by blocking two proteins called CDK4 and CDK5. These proteins can cause the cell cycle to pause, giving the healthy cells time to repair any damage caused by chemotherapy. It also helps boost the effectiveness of certain cancer treatments that use the immune system, by helping T-cells recognize and attack cancer cells.

When to interrupt dosage

The portion of Cosela is contingent upon the determined circumstances, such as Malignant Neoplasms, Pharmacotherapy and Pharmacotherapy. The amount of dosage is also contingent upon the technique of delivery as mentioned in the table below.
Condition
Dosage
Administration
Pharmacotherapy
, 30.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous,
Bone Marrow
, 30.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous,
Therapeutic procedure
, 30.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous,
Pharmacotherapy
, 30.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous,
Malignant Neoplasms
, 30.0 mg/mL
Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous,

Warnings

Cosela has a single contraindication, and thus should not be employed if any of the conditions in the following table are present.Cosela Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Trilaciclib may interact with Pulse Frequency
There are 20 known major drug interactions with Cosela.
Common Cosela Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The excretion of Abemaciclib can be decreased when combined with Trilaciclib.
Acenocoumarol
Major
The metabolism of Acenocoumarol can be increased when combined with Trilaciclib.
Aminophylline
Major
The metabolism of Aminophylline can be increased when combined with Trilaciclib.
Anagrelide
Major
The metabolism of Anagrelide can be increased when combined with Trilaciclib.
Axitinib
Major
The metabolism of Axitinib can be increased when combined with Trilaciclib.
Cosela Toxicity & Overdose RiskThere is limited information about overdosing on trilaciclib. If a person experiences severe injection site reactions, allergic reactions, or lung disease, they should stop taking the drug immediately.

Cosela Novel Uses: Which Conditions Have a Clinical Trial Featuring Cosela?

An ongoing investigation is assessing the efficacy of Cosela in providing therapeutic bone marrow procedures and tumor suppression for various malignancies.
Condition
Clinical Trials
Trial Phases
Malignant Neoplasms
13 Actively Recruiting
Phase 1, Phase 2, Phase 3
Therapeutic procedure
0 Actively Recruiting
Pharmacotherapy
0 Actively Recruiting
Pharmacotherapy
0 Actively Recruiting
Bone Marrow
0 Actively Recruiting

Patient Q&A Section about cosela

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Cosela FDA approved?

"On February 12th, 2021, the FDA approved trilaciclib (Cosela, G1 Therapeutics) to lower the rate of chemotherapy-induced myelosuppression (CIM) in adult patients with extensive-stage small-cell lung cancer (ES-SCLC) receiving platinum/etoposide-containing or topotecan-containing first-line therapy."

Answered by AI

Is Cosela chemotherapy?

"Trilaciclib is given before chemotherapy to help reduce the number of low blood cell counts caused by damage to bone marrow from chemotherapy."

Answered by AI

What is chemotherapy-induced myelosuppression?

"Myelosuppression is a suppression of bone marrow activity which results in a decreased production of blood cells. This is a common side effect of chemotherapy, and can range from mild to severe."

Answered by AI

What is Cosela used for?

"COSELA is a prescription medication that helps to reduce the occurrence of low blood cell counts that are caused by damage to bone marrow from chemotherapy. COSELA is typically used to treat adults who are taking certain chemotherapies, such as platinum/etoposide or topotecan, for extensive-stage small cell lung cancer."

Answered by AI

Clinical Trials for Cosela

Have you considered Cosela clinical trials? We made a collection of clinical trials featuring Cosela, we think they might fit your search criteria.Go to Trials
Image of Research Site - Orange City in Orange City, United States.

Serplulimab + Chemotherapy for Small Cell Lung Cancer

18 - No maximum age
All Sexes
Orange City, FL
This trial is testing two different treatment combinations for patients with extensive-stage small cell lung cancer who have not received any prior treatment. One group will receive a new drug called Serplulimab along with standard chemotherapy, while the other group will receive an existing drug called Atezolizumab with the same chemotherapy. Both immunotherapy drugs aim to help the immune system fight cancer, and the chemotherapy drugs work by killing cancer cells. Atezolizumab has been shown to improve survival in small-cell lung cancer when combined with chemotherapy, changing the standard first-line therapy.
Phase 3
Recruiting
Quick Reply
Has No Placebo
Research Site - Orange City (+99 Sites)Shanghai Henlius Biotech
Have you considered Cosela clinical trials? We made a collection of clinical trials featuring Cosela, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security